Patent ID: 8501427
Filing Date: 2013-08-06
Classification: C07K,G01N

Abstract:
1. A method for determining a risk factor for a complement mediated disease in an individual comprising: a) obtaining a plasma sample from an individual to be tested; b) exposing said sample to at least one antibody, or antigen-binding fragment thereof, produced by a deposited hybridoma having an ECACC accession number A 07042601 (His402 variant) and specific for a histidine 402 variant (His402 variant) of Complement Factor H, and/or at least one antibody, or antigen-binding fragment thereof, produced by a deposited hybridoma having an ECACC accession number A 08011002 (Tyr402 variant) and specific for a tyrosine 402 variant (Tyr402 variant) of Complement Factor H; c) determining specific binding of said antibody to plasma Complement Factor H and where binding of the histidine specific antibody produced by the deposited hybridoma having the ECACC accession number A 07042601 takes place concluding that the histidine 402 variant is present, or where binding of the tyrosine specific antibody produced by the deposited hybridoma having the ECACC accession number A 08011002 takes place concluding that the tyrosine 402 variant is present; and d) where the histidine 402 variant is present, concluding that the individual either has, or is at increased risk of developing a complement mediated disease, or where the binding of only the tyrosine specific antibody indicates a homozygous state for the tyrosine 402 variant, i.e. that there is no histidine 402 variant present, concluding that the individual is at reduced risk of developing a complement mediated disease.